Compare Acadia Healthcare Company Inc (ACHC) vs TG Therapeutics Inc (TGTX) Price & Performance

ACHC trades at $31.70, down 0.25% on the day, with neutral technical indicators and strong analyst support (68% buy ratings). The company has beaten earnings estimates for three consecutive quarters, though profitability remains challenged with a -33.44% net income margin. Recent Q2 2026 results showed revenue of $865.8 million with earnings beating expectations at $0.38 per share.

While facing profitability challenges and ongoing legal investigations, ACHC benefits from strong analyst consensus with a $36.00 price target representing 13.6% upside. The stock offers potential through continued earnings beats and operational improvements, but investors must weigh legal risks against the company's turnaround strategy and behavioral healthcare demand growth.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.